MAPT and Alzheimer disease: AD is characterized by specific neuropathological and biomarker changes, including extracellular accumulation of amyloid-beta (Aβ) peptides and intraneuronal NFTs formed by aggregation of hyperphosphorylated or abnormally-phosphorylated tau proteins [99, 100].